Архитектура Аудит Военная наука Иностранные языки Медицина Металлургия Метрология
Образование Политология Производство Психология Стандартизация Технологии


III. Организационные аспекты внедрения протокола



16. Список разработчиков:

1) Кабулбаев К.А. - доктор медицинских наук, доцент кафедры внутренних болезней центра последипломного и дополнительного профессионального образования НИИ кардиологии и внутренних болезней.

2) Карабаева А.Ж. - доктор медицинских наук, руководитель центра последипломного и дополнительного профессионального образования НИИ кардиологии и внутренних болезней.

17. Указание на отсутствие конфликта интересов: конфликта интересов нет.

18. Рецензенты: Туганбекова С.К. - Главный внештатный нефролог Министерства здравоохранения Республики Казахстан.

19. Указание условий пересмотра протокола: Пересмотр протокола производится не реже, чем 1 раз в 5 лет, либо при поступлении новых данных по диагностике и лечению соответствующего заболевания, состояния или синдрома.

Список использованной литературы

1. Lameson J.L., Loscalzo J. Harrison's Nephrology and Acid-Based Disorders. Edition 17th, 2010, New-York.

2. Клинические рекомендации. Стандарты ведения больных. Мухин Н.А., Козловская Л.В., Шилов Е.М. Выпуск 2, Гэотар Медиа, 2008 г., 1376 с.

3. Нефрология. Национальное руководство. Под ред. Мухина Н.А. Гэотар Медиа, 2008 г, 716 с.

4. Tune B.M., Mendoza S.A. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:824.

5. Nolasco F., Cameron J.S., Heywood E.F., et. al. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 1986; 29:1215.

6. Fujimoto S., Yamamoto Y., Hisanaga S., et. al. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 1991; 17:687.

7. Nakayama M., Katafuchi R., Yanase T., et. al. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39:503.

8. Korbet S.M., Schwartz M.M., Lewis E.J. Minimal-change glomerulopathy of adulthood. Am J Nephrol 1988; 8:291.

9. Мак S.K., Short C.D., Mallick N.P. Long-term outcome of adult-onset minimal-change nephropathy Nephrol Dial Transplant 1996; 11:2192.

10. Arneil G.C., Lam C.N. Long-term assessment of steroid therapy in childhood nephrosis. Lancet 1966; 2:819.

11. Tse К.С., Lam M.F., Yip P.S., et. al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 2003; 18:1316.

12. Meyrier A. Nephrotic focal segmental glomerulosclerosis in 2004: an update. Nephrol Dial Transplant 2004; 19:2437.

13. Gipson D.S., Trachtman H., Kaskel F.J., et. al. Clinical trial of focal segmental glomerulosclerosis in children and young adults, допа Int 2011; 80:868.

14. Muso E., Mune M., Yorioka N., et. al. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 2007; 67:341.

15. Joy M.S., Gipson D.S., Dike M., et. al. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol 2009; 4:39.

16. Hausmann R., Kuppe C., Egger H., et. al. Electrical forces determine glomerular permeability. J Am Soc Nephrol 2010; 21:2053.

17. Reiser J., von Gersdorff G., Loos M., et. al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113:1390.

18. Schonenberger E., Ehrich J.H., Haller H., Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011; 26:18.

19. Gbadegesin R., Lavin P., Foreman J., Winn M. Pathogenesis and therapy of focal segmental glomerulosclerosis: an update. Pediatr Nephrol 2011; 26:1001.

20. Chen T., Lv Y., Lin F., Zhu J. Acute kidney injury in adult idiopathic nephritic syndrome. Ren Fail 2011; 33:144.

21. Frisch G., Lin J., Rosenstock J., et. al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20:2139.

22. Le W., Liang S., Hu Y., et. al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 2012; 27:1479.

23. Kunz R., Friedrich C., Wolbers M., Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30.

24. Orlowski T., Rancewicz Z., Lao M., et. al. Long-term immunosuppressive therapy of idiopathic membranoproliferative glomerulonephritis. Klin Wochenschr 1988; 66:1019.

25. Cattran D.C., Cardella C.J., Roscoe J.M., et. al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 1985; 27:436.

26. Faedda R., Satta A., Tanda F., et. al. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 1994; 67:59.

27. Bhat P., Weiss S., Appel G.B., Radhakrishnan J. Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases. Am J Kidney Dis 2007; 50:641.

28. Vilayur E., Trevillian P., Walsh M. Monoclonal gammopathy and glomeralopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol 2009; 5:54.

29. Dillon J.J., Hladunewich M., Haley W.E., et. al. Rituximab therapy for type I membranoproliferative glomerulonephritis. Clin Nephrol 2012; 77:290.

30. Jones G., Juszczak M., Kingdon E., et. al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 2004; 19:3160.

31. Choi M.J., Eustace J.A., Gimenez L.F., et. al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098.

32. Bayazit A.K., Noyan A., Cengiz N., Anarat A. Mycophenolate mofetil in children with multidrug-resistant nephrotic syndrome. Clin Nephrol 2004; 61:25.

33. Bagheri N., Nemati E., Rahbar K., et. al. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med 2008; 11:26.

34. Cattran D.C. Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol 1991; 35 Suppll: S43.

35. Matsumoto H., Shibasaki T., Ohno I., et. al. [Effect of cyclosporin monotherapy on proteinuria in a patient with membranoproliferative glomerulonephritis]. Nihon Jinzo Gakkai Shi 1995; 37:258.

36. Haddad M., Lau K., Butani L. Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol 2007; 22:1787.

37. Donadio J.V. Jr., Anderson C.F., Mitchell J.C. 3rd, et. al. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med 1984; 310:1421.

38. Zauner I., Bohler J., Braun N., et. al. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol Dial Transplant 1994; 9:619.

39. Zimmerman S.W., Moorthy A.V., Dreher W.H., et. al. Prospective trial of Warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med 1983; 75:920.

40. Harmankaya O., Basturk T., Ozttirk Y., et. al. Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol 2001; 33:583.

41. Servais A., Fremeaux-Bacchi V., Lequintrec M., et. al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44:193.

42. Habbig S., Mihatsch M.J., Heinen S., et. al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75:1230.

43. Fakhouri F., Fremeaux-Bacchi V., Noel L.H., et. al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494.

44. Radhakrishnan S., Lunn A., Kirschfink M., et. al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366:1165.

45. Bomback A.S., Smith R.J., Barile G.R., et. al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7:748.

46. Licht C., Weyersberg A., Heinen S., et. al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005; 45:415.

 

 


Поделиться:



Последнее изменение этой страницы: 2019-03-22; Просмотров: 285; Нарушение авторского права страницы


lektsia.com 2007 - 2024 год. Все материалы представленные на сайте исключительно с целью ознакомления читателями и не преследуют коммерческих целей или нарушение авторских прав! (0.02 с.)
Главная | Случайная страница | Обратная связь